United Therapeutics Corporation or ImmunityBio, Inc.: Who Manages SG&A Costs Better?

Who Manages SG&A Costs Better: United Therapeutics or ImmunityBio?

In the competitive landscape of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. From 2014 to 2023, United Therapeutics Corporation consistently outperformed ImmunityBio, Inc. in controlling these costs. United Therapeutics maintained an average SG&A expense of approximately $394 million annually, while ImmunityBio's average was around $90 million. Notably, United Therapeutics' SG&A expenses peaked in 2022 at $487 million, a 30% increase from 2014, reflecting strategic investments in growth. In contrast, ImmunityBio's expenses fluctuated more dramatically, with a significant spike in 2015, reaching $226 million, before stabilizing. This data suggests that United Therapeutics has a more consistent approach to managing operational costs, potentially providing a competitive edge. Investors and stakeholders should consider these trends when evaluating the financial health and strategic direction of these companies.